Eagle Pharmaceuticals stock faces October 16 settlement deadline
Published on 10/07/2026 at 03:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eagle Pharmaceuticals stock (ISIN US2697961082) was last at USD 0.970 on OTC Markets on October 6, 2026, giving the company a market capitalization of USD 12.63 million. The central investor event is a USD 9.5 million securities settlement approved on August 19, 2026, with claims due by October 16, 2026, according to OpenClassActions.
Settlement reaches its deadline
The settlement fund covers investors who purchased Eagle common stock between August 9, 2022 and October 1, 2024. The court entered final judgment on August 19, 2026, while the claim window remains open through October 16, 2026, the settlement page states.
Law360 listed the final approval as an August 20, 2026 legal development and described the agreement as a USD 9.5 million investor deal. The settlement resolves claims related to alleged disclosures about Eagle revenue and its Pemfexy product; the defendants denied wrongdoing, according to the settlement account.
OTC listing changes the trading picture
Eagle common stock traded on the Nasdaq Global Market during the settlement class period. Nasdaq suspended trading on October 3, 2024, and the stock moved to the OTC Expert Market under the same ticker on October 4, 2024, according to OpenClassActions.
That listing change helps explain the wide market-data spread. On October 6, 2026, the USD 0.970 quote stood 55.91 percent below the USD 2.200 52-week high and above the USD 0.001 52-week low. The same quote page lists Eagle in the healthcare sector and specialty and generic drug manufacturing industry.
Next earnings date is November 9
Investing.com lists November 9, 2026 as Eagle Pharmaceuticals' next earnings date. The company describes its portfolio as including products for oncology, central nervous system conditions and critical care, including RYANODEX, BENDEKA, PEMFEXY and BYFAVO, according to its investor page at Eagle Pharmaceuticals.
For investors, the settlement deadline and the OTC trading venue define the immediate framework around EGRX. The USD 12.63 million market capitalization and the 52-week range show a security whose quoted value remains highly sensitive to limited trading liquidity and legal-case developments.
EGRX remains below its yearly high
EGRX was last at USD 0.970 on OTC Markets on October 6, 2026. The quote was 55.91 percent below the USD 2.200 52-week high.
Eagle Pharmaceuticals stock facts
- Company: Eagle Pharmaceuticals, Inc.
- ISIN: US2697961082
- Ticker: EGRX
- Trading venue: OTC Markets
- Price (as of October 6, 2026): USD 0.970
- Market capitalization: USD 12.6 million (as of October 6, 2026)
- 52-week range: USD 0.001-2.200 (as of October 6, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Upcoming dates for Eagle Pharmaceuticals stock
- October 16, 2026: Settlement claim deadline
- November 9, 2026: Next earnings date
